-
12m 24sPart 3 | Session 2 DIGIT-HF: Cardiac Glycosides in HFrEF
-
12m 36sPart 3 | Session 3 BETAMI-DANBLOCK: Beta-blockers after MI
-
14m 3sPart 3 | Session 4 ESC 25 Guidelines Discussion: Management of Dyslipidaemias
-
14m 30sPart 3 | Session 5 2025 ESC/EACTS Guidelines for the Management of Valvular Heart Disease
-
27m 8s
-
4m 15sPart 4 | Session 1 TRISCEND II Trial: TTVR Outcomes by Baseline TR Severity
-
3m 52sPart 4 | Session 2 The VICTOR & VICTORIA Pooled Analysis
-
5m 10s
-
7m 42sPart 4 | Session 4 ESVM Guidelines on Interventional Treatment of Venous Thromboembolism
-
7m 12s
-
6m 54sPart 4 | Session 6 STEEER-AF Cluster Randomised Trial by the ESC and EHRA
-
10m 5sPart 4 | Session 7 NEWTON-CABG CardioLink-5: Evolocumab and Saphenous Vein Graft Patency
-
7m 43s
-
6m 35sPart 4 | Session 9 SWEDEPAD 1 and 2: Drug-Coated Devices in Peripheral Arterial Disease
-
5m 6sPart 4 | Session 10 Lifetime Benefits of Combination Therapy in HFpEF
-
3m 53sPart 4 | Session 11 REBOOT-CNIC: Beta-blockers After Infarction with LVEF Greater Than 40%
-
4m 31sPart 4 | Session 12 ODYSSEY-HCM: Mavacamten in Non-obstructive Hypertrophic Cardiomyopathy
-
6m 37sPart 4 | Session 13 Pooled MACE Data for Obicetrapib
-
8m 9sPart 4 | Session 14 STRIDE: Outcomes by Sex
-
4m 27sPart 4 | Session 15 The SEMA-VR CardioLink-15 Trial
-
7m 20sPart 4 | Session 16 The CARUSO Trial: Carotid Plaques Stabilisation and Regression with Evolocumab
-
3m 38sPart 4 | Session 17 EMORI-HCM: Electromagnetically Optimised Right Ventricular Pacing for oHCM
-
47m 54sPart 1 | Session 1 View from the Thoraxcenter: ESC 25 Late-breaking Science Wrap-Up
-
36m 33sPart 1 | Session 2 View from the Thoraxcenter: What's Hot at ESC 25?
-
11m 8sPart 2 | Session 1 Day 4 Wrap-Up with Dr Alasnag and Dr Al-Shaibi
-
19m 8sPart 2 | Session 2 Day 3 Wrap-Up with Dr Alasnag and Dr Al-Shaibi
-
13m 11sPart 2 | Session 3 Day 2 Wrap-Up with Dr Alasnag and Dr Al-Shaibi
-
14m 10sPart 2 | Session 4 Day 1 Wrap-Up with Dr Alasnag and Dr Al-Shaibi
ESC Congress 2025 - Vericiguat did not reduce the risk of cardiovascular mortality and hospitalization in heart failure with reduced ejection fraction, fewer cardiovascular deaths and all-cause deaths were observed.
Host, Dr Harriette Van Spall (McMaster University, CA) is joined on-site at ESC Congress 2025 in Madrid by Dr Faiez Zannad (University of Lorraine, FR) to discuss pivotal results from the VICTOR (NCT05093933) trial.
The VICTOR programme assessed vericiguat (MK-1242) safety and efficacy in 6105 heart failure with reduced ejection fraction patients, encompassing both acute decompensated and chronic stable populations. The trials compared three vericiguat dosing regimens (2.5, 5.0, and 10.0 mg once daily) against placebo, measuring time to first occurrence of the composite primary endpoint of cardiovascular death or heart failure hospitalisation.
Findings showed that over 18.5 months follow-up, the primary outcome event of cardiovascular death or HF hospitalization had occurred in 18% of patients in the vericiguat group, and 19.1% of patients on the placebo group. Although vericiguat did not improve the primary composite endpoint, there were fewer cardiovascular deaths and all-cause deaths, supporting the use of the drug in ambulatory patients with HFrEF in addition to contemporary therapies.
Recorded onsite at ESC Congress 2025 in Madrid.
Editors: Jordan Rance and Yazmin Sadik.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David-Ben-Harosh.
Support: This is an independent interview produced by Radcliffe Cardiology.
Dive into our coverage of ESC Congress 2025 for groundbreaking trial results and discussions with expert faculty.
- Watch our View From the Thoraxcenter series for practice-focused reviews of the most anticipated trials from interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen.
- Watch our Wrap-Up series led by Dr Mirvat Alasnag summarising the key take-aways from each day of the congress.
- For clinical trial data from principal investigators, keep up with Dr Harriette Van Spall's Late-Breaker Discussion series.
- Our concise, accessible Expert Interviews will focus on the current data and it's impact on clinical practice.
- Don't miss the Highlights series to stay ahead of the curve in each field.
- In the Journal Discussions series, authors of ECR Journal explore their special focuses in depth.
More from this programme
Part 1
View from the Thoraxcenter: What's Hot at ESC 25?
Part 2
Daily Wrap Ups with Dr Mirvat Alasnag
Part 3
Hot-line Discussions with Dr Harriette Van Spall
Part 4
Expert Interviews
Part 5
Highlights
Faculty Biographies
Faiez Zannad
Professor of Therapeutics and Cardiology, Head of CIC
Prof Faiez Zannad is Professor of Therapeutics & Cardiology and Head of the Division of Heart Failure, Hypertension and Preventive Cardiology for the department of Cardiovascular Disease of the Academic Hospital (CHU) in Nancy and the Director of the Clinical Investigation Centre (Inserm-CHU).
Prof Zannad is currently the Chairman of the ESC Working group on Pharmacology and Drug Therapy as well as a Boardmember of the ESC Heart Failure Association. He is Past-President of the French Society of Hypertension.
Prof Zannad is Co-Editor-in-Chief for Fundamental and Clinical Pharmacology, the official journal of the European Pharmacology Societies Federation (EUPHAR). He chairs and organises annual international meetings on CardioVascular Clinical Trials (CVCT) and on Biomarkers in Heart Failure.
Harriette Van Spall
Associate Professor of Medicine, Director of E-Health and Virtual Care
Dr Harriette Van Spall is an Associate Professor of Medicine and cardiologist and serves as Director of E-Health at McMaster University, Canada. She completed her medical and postgraduate clinical training at the University of Toronto and earned a Master of Public Health degree at Harvard University, US. Dr Van Spall is a Canadian Institutes of Health Research-funded clinical trialist and researcher with a focus on heart failure, health services, and health disparities.
She has garnered more than $4 million in research funding, has won several research awards, and has published her work in high-impact medical journals. She is an invited speaker, media correspondent, and editorial board member active in peer review at several high-impact medications journals and grant funding agencies, including Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada.
Dr Van Spall is an Editorial Board…
Comments